Replagal

Selected form

Agalsidase Alfa

Method of action: Other Alimentary Tract And Metabolism Products

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Replagal

Quick Facts

Property	Description
Active ingredient	Agalsidase alfa (rh α-galactosidase A)
Form	Concentrate for solution for infusion
Pharmacological class	Lysosomal enzyme, Hydrolase
Common use	Enzyme Replacement Therapy (ERT)
Origin	Recombinant, Biotechnology-derived

What Type of Medicine is Replagal (Agalsidase Alfa)?

Replagal is a specialized, biotechnology-derived medicine used as an Enzyme Replacement Therapy (ERT), a class of therapeutics that is clinically recognized for providing specific replacement proteins. Its active ingredient is Agalsidase alfa, which is classified as a lysosomal enzyme and a hydrolase. The medicine functions as a substitute for the naturally occurring human enzyme α-galactosidase A (α-Gal A), which is deficient in the patients it targets.

This therapeutic agent is considered a biopharmaceutical because its protein structure is large and complex, synthesized using advanced recombinant DNA technology. This approach is necessary to address the underlying metabolic cause of the condition by supplying the specific enzymatic function the body cannot naturally provide.

Composition, Origin, and Form

The active ingredient, Agalsidase alfa, is entirely recombinant in origin, produced in a human cell line by genetic engineering technology. Replagal is provided as a concentrate for solution for infusion and is administered exclusively via the intravenous (IV) route. This IV preparation is crucial because the large protein structure of the replacement enzyme would be degraded by digestive processes if taken orally. Its formulation is distinct from its analogue, Agalsidase beta, as it features a unique glycosylation pattern stemming from its specific manufacturing process.

What is the General Purpose of This Therapy?

The general purpose of this therapy is to perform a crucial chemical action: the breakdown (hydrolysis) of a specific fatty substance called globotriaosylceramide.

What side effects are possible with Replagal?

Possible Side Effects and Safety Information

The safety profile of Replagal (Agalsidase alfa), a recombinant enzyme replacement therapy, is primarily characterized by adverse reactions related to the intravenous administration of the protein, known as Infusion-Associated Reactions (IARs). These effects are classified and grouped by regulatory authorities according to frequency and the body system affected.

Frequency and Systemic Grouping

Adverse events are frequently categorized in official documents:

Classification	Common Examples	System-Organ Class Involved
Very Common (ge 1/10)	Rigors, headache, fatigue, nausea, pyrexia, dizziness, neuropathic pain, cough, myalgia	General disorders, Nervous system, Musculoskeletal
Common (ge 1/100 to <1/10)	Hypersensitivity, atrial fibrillation, tachycardia, chest tightness, peripheral swelling	Immune system, Cardiac disorders, Vascular disorders
Uncommon (ge 1/1,000 to <1/100)	Anaphylactic reaction, tachyarrhythmia	Immune system, Cardiac disorders

Serious Reactions and Safety Context

Serious adverse reactions officially documented include severe hypersensitivity or anaphylactic reactions. Furthermore, cardiac events such as myocardial ischemia and heart failure have been reported, particularly in individuals with pre-existing cardiac manifestations of Fabry disease, where the hemodynamic stress from IARs may represent an increased risk.

Time-related patterns show that IARs generally occur within the first few months of treatment initiation and are noted to decrease in incidence and severity over time. Specific co-administration restrictions are documented for drugs that may inhibit intra-cellular alpha-galactosidase activity, such as chloroquine or amiodarone. Regulatory caution is also noted for use in the paediatric population and during pregnancy and lactation.

Overdose and Emergency Response

The official regulatory documentation for Agalsidase alfa does not define a specific syndrome resulting from an acute overdose, as there is no clinical experience with over-administration. Emergency guidance is therefore structured around managing severe acute reactions associated with the infusion.

Overdose Scope

Documented overdose presentations:

Lack of Specific Syndrome: No specific clinical experience with acute overdose is documented in official regulatory labeling.
Severe Acute Symptoms: Symptoms requiring immediate medical attention include pyrexia, rigors, tachycardia, urticaria, nausea/vomiting, angioneurotic oedema with throat tightness, stridor, and swollen tongue.

Physiological systems affected (as stated in label):

Cardiovascular System: Acute reactions may lead to cardiac arrhythmias, myocardial ischemia, or heart failure due to hemodynamic stress.
Respiratory/Laryngeal: Manifestations of severe hypersensitivity include stridor and swollen tongue.

Population-specific overdose notes (if applicable):

Pre-existing Cardiac Disease: Patients with pre-existing cardiac manifestations of Fabry disease are specifically noted to be at risk for severe cardiac events during infusion reactions.

Emergency-response statements (as written in official documents):

Immediate Attention Required: Medical attention must be sought immediately upon the occurrence of acute reactions.
Discontinuation: For severe hypersensitivity reactions, the administration should be discontinued immediately, and appropriate treatment should be initiated following current medical standards.

Overdose Classifications (high-level)

Severity classification (as defined in official documents):

Severe or Life-Threatening: The events that govern the emergency protocol are classified as severe hypersensitivity or anaphylactic-type reactions.

Regulatory basis (EMA / FDA / etc.):

Official prescribing information.

Resulting overdose structure

The official overdose profile is defined by an emergency protocol for managing severe acute adverse events. This approach is mandated because of the lack of a documented acute overdose syndrome, establishing severe Infusion-Related Reactions as the primary trigger for seeking immediate medical help.

Therapeutic Uses of Replagal

What Replagal Treats: Main Uses and Benefits

Replagal (Agalsidase alfa) is a long-term Enzyme Replacement Therapy (ERT) applied in addressing patients diagnosed with Fabry disease. The primary goal of this therapy is to support the management of the progressive nature of the condition and offers symptomatic relief that helps with challenging symptoms that interfere with daily functioning.

Therapeutic Focus and Patient Benefits

This treatment is commonly used in the chronic setting to support the management of disease progression by helping to address the accumulation of the fatty substrate GL-3 in critical tissues. The therapeutic benefit supports the management of symptoms linked to organ-specific functional stress, which contributes to the general well-being during symptomatic phases. Specifically, it is applied in addressing recurrent, burning neuropathic pain (acroparesthesia), symptoms related to autonomic dysfunction (e.g., hypohidrosis), and chronic gastrointestinal distress.

“Therapy supports the patient during difficult episodes by easing distress and assists with maintaining a sense of stability when symptoms are more noticeable.”

The treatment is extended to patients across the Fabry spectrum, including both adults and children (typically ages 7 years and older), and both males and females who are susceptible to progressive GL-3 accumulation.

Quick Fact: Support for Neuropathic Pain Symptoms
Replagal is considered relevant for managing episodes of severe acroparesthesia, a frequent symptom that often interferes with routine activities.

Regulatory References

European Medicines Agency (EMA) overview

Eligibility and Restrictions for Use

Who Can and Cannot Use Replagal?

Eligibility for Replagal (Agalsidase alfa) is defined by official regulatory bodies, primarily based on diagnosis and specific patient characteristics. This medicine is indicated for long-term enzyme replacement therapy in patients with a confirmed diagnosis of Fabry Disease (alpha-galactosidase A deficiency).

Official Restrictions and Contraindications

Classification	Rule (Based on Regulatory Labeling)
Absolute Contraindication	Must not be used in patients with known hypersensitivity or severe allergic reaction to the active substance (Agalsidase alfa) or any of the product’s excipients.
Established Age Groups	Use is established in adults and the pediatric population aged 7 to 18 years.
Use Not Established	Safety and efficacy have not yet been established for children aged 0–6 years and for elderly patients aged ge 65 years; no dosage recommendation can be made for these groups.
Renal Impairment Status	While no dose adjustment is required, the presence of extensive renal damage (e.g., eGFR < 60, mL/min) may limit the renal response to the therapy.
Pregnancy and Lactation	Caution should be exercised when prescribing to pregnant or breastfeeding women, as data for these groups is very limited or unknown.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official regulatory profile for Replagal (Agalsidase alfa) defines interaction patterns through specific substance restrictions and mandatory procedural constraints. This information strictly details formal interactions and the confirmed absence of certain metabolic pathways, without addressing therapeutic outcomes or dosage.

Documented Interaction Restrictions

Category	Regulatory Statement
Enzyme Activity Inhibitors	Co-administration is formally restricted with medicines known to inhibit the intra-cellular alpha-galactosidase activity of the replacement enzyme.
Specific Restricted Medicines	Chloroquine, Amiodarone, Benoquin, and Gentamicin should not be co-administered, a restriction documented in regulatory prescribing information.
Metabolic Interaction Status	The alpha-galactosidase A enzyme is documented as an unlikely candidate for involvement in Cytochrome P450 (CYP)-mediated drug-drug interactions.
Procedural Timing Rule	The medicine must not be infused concomitantly in the same intravenous line with any other agents, a constraint specified for administration protocols.

Undocumented Interactions

Regulatory labels confirm that no specific interactions are documented concerning food, alcohol, herbal products, or nutritional supplements. No transporter-mediated interactions are formally reported. The documented profile establishes clear boundaries primarily to protect the biological activity of the infused enzyme.

Mechanism of Action

Enzyme Replacement and Lysosomal Catabolism

Replagal functions as an enzyme replacement therapy, supplying a functional, recombinant copy of the alpha-galactosidase A (alpha-Gal A) enzyme. This enzyme targets and facilitates the breakdown of its specific substrate, Globotriaosylceramide (Gb3), primarily within the cell's lysosomes . This direct catalytic action addresses the deficiency in the catabolic pathway, facilitating the degradation of the stored substrate within the lysosome.

Cellular Targeting and Systemic Clearance

The drug is selectively delivered to cells via Mannose-6-Phosphate (M6P) receptors, ensuring transport to the lysosomes of cells in the vascular endothelium and in key organ parenchyma. This focused substrate reduction is a key mechanistic cascade that modulates the cellular pathology associated with substrate accumulation. This action modulates the pathological stress associated with substrate storage, leading to changes in organ systems and vascular structure.

Dosage and Administration Information

How to Use Replagal: Official Administration Guidelines

Replagal (agalsidase alfa) is an Intravenous (IV) Enzyme Replacement Therapy (ERT) that must be administered according to specific procedural and dosing parameters for long-term use in Fabry disease.

Standard Dosing and Frequency

The medicine is administered at a fixed dose of 0.2 mg per kg of body weight, given every other week (EOW). This regimen is the standard, fixed-interval dosing pattern established for Replagal.

Preparation and Administration Specifics

The treatment requires the concentrated solution to be aseptically diluted in 100 mL of 0.9% Sodium Chloride (NaCl) solution for infusion. The diluted preparation must be mixed gently but not shaken. The final solution is then administered intravenously over a 40-minute period. It is an explicit procedural constraint that the infusion must use an IV line with an integral filter, and the solution must not be infused concomitantly with any other agents.

Use in Specific Populations

This 0.2 mg/kg EOW regimen is suggested for children between 7 and 18 years of age. No dose adjustment is necessary for patients with renal impairment. However, safety and efficacy have not been established in children aged 0–6 years or in older adults (age >65), and no regimen is currently recommended for these groups. Treatment should be supervised by a physician experienced in inherited metabolic diseases.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Replagal (Agalsidase Alfa)

The research foundation for Replagal consists of various types of clinical studies, ranging from short-term, controlled trials to large, international, long-term observational registries. These studies are used in research exploring how outcomes related to systemic or functional imbalance and patient-reported outcomes describing perceived discomfort change over time. The goal of this research is to build the broader evidence landscape describing the use of this enzyme replacement therapy for Fabry disease.

Evidence for Managing Neuropathic Pain (Acroparesthesia)

This section will summarize the structure of the initial randomized controlled trials (RCTs) and subsequent open-label studies that was studied for how outcomes related to physical discomfort changed over time. Short-term, placebo-controlled trials were evaluated in controlled settings to research whether outcomes related to physical discomfort (acroparesthesia) were measured differently in adult male patients.

Findings describe patterns observed in the studies, including measurements of pain severity. Follow-up research monitored patient experiences over several years. What remains uncertain is the durability of these patterns over very extended periods, as the original controlled studies had limited follow-up durations (typically six months).

Evidence for Managing Progressive Organ Changes

This section will cover the research focused on two major areas of Fabry disease progression: changes in cardiac structure (like left ventricular mass) and the rate of renal (kidney) function decline. The available data from short-term RCTs and long-term observational registries for these endpoints are described.

Research on Cardiac Structure and Function

Studies exploring heart structure utilized both short-term RCTs and extensive long-term observational registry data. Research examined changes in the thickness of the heart muscle, specifically Left Ventricular Mass Index (LVMI). Studies monitored specific measurements for Left Ventricular Mass in the observed populations. A key limitation is that the initial controlled trials for cardiac endpoints often had modest sample sizes.

Research on Kidney Function and Biomarkers

Research exploring kidney outcomes was evaluated in a combination of controlled studies and long-term observational settings. Studies explored changes in renal function, specifically the annualized rate of change in eGFR, and monitored the levels of the fatty substance globotriaosylceramide ( GL-3) as a biomarker. Findings for kidney function in the short-term controlled studies were mixed.

Research Gaps and Areas of Uncertainty

This final section is used in research exploring the main limitations of the existing research landscape. The evidence quality varies across studies, with certain aspects of long-term change primarily understood through observational registry data rather than controlled trials. The follow-up durations were limited in the original placebo-controlled studies, meaning that long-term effects are not fully established based on the highest level of controlled evidence.

Frequently Asked Questions (FAQ)

Common questions about Replagal (FAQ)

Q: What is the active ingredient in Replagal?

A: The active substance in Replagal is agalsidase alfa. This substance is a form of the human enzyme alpha-galactosidase A that is produced using genetic engineering technology. Regulatory documents state that it is used as an enzyme replacement for the natural enzyme that is deficient in patients with Fabry disease.

Q: What is Replagal used for?

A: Replagal is indicated as an enzyme replacement therapy (ERT) for patients with confirmed Fabry disease. This includes both adults and children aged 7 years and older. According to the official product information, it is used to address the enzyme deficiency characteristic of the condition.

Q: How does Replagal work to treat Fabry disease?

A: Replagal acts as a replacement for the deficient alpha-galactosidase A enzyme that causes Fabry disease. Studies and official information indicate that this enzyme breaks down a fatty substance called Gb3 (globotriaosylceramide) that otherwise builds up in the body's cells. By breaking down Gb3, the therapy aims to reduce the accumulation of this substance and related organ damage.

Q: Are there any known drug interactions with Replagal?

A: Official product information states that caution is advised when Replagal is administered with certain medications, including chloroquine, amiodarone, benoquin, or gentamicin. These medicines may interfere with the activity of the enzyme Replagal provides. The full list of known or potential interactions is available in the official prescribing information.

Q: Can Replagal be administered with other treatments for Fabry disease?

A: Regulatory documents indicate there is limited experience regarding the use of Replagal in combination with conventional treatments for Fabry disease, such as enzyme stabilizers. The safety of such combinations has not been fully established in official trials. Decisions about using Replagal with other treatments should be made in consultation with a healthcare professional.

Q: What is the recommended storage temperature for Replagal?

A: Replagal must be stored in a refrigerator at a temperature between 2°C and 8°C. Do not freeze the medicine, as freezing can damage the solution and render it unusable. According to the official product information, it should also be kept in the original carton to protect it from light.

How should Replagal be stored and disposed of?

How to Store and Dispose of Replagal?

Replagal (agalsidase alfa) must be stored under specific conditions to maintain its effectiveness.

Storage Requirements

Condition	Requirement
Temperature	Store in a refrigerator (2 C to 8 C). Do not freeze the vial.
Light	Keep the vial in the outer carton to protect from light.
Accessibility	Store out of the reach and sight of children.
Integrity	Do not use after the expiry date or if the solution is discoloured or contains foreign particles.

Handling and Stability

The product is for single use only. Since it contains no preservative, aseptic technique must be used during dilution with 0.9% sodium chloride solution. The diluted solution should ideally be used immediately. If immediate use is not possible, it may be stored for a maximum of 24 hours at 2 C to 8 C under validated conditions.

Disposal Rules

Any unused product or waste material must be disposed of according to local requirements. Do not throw away this medicine via wastewater or household waste to help protect the environment.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.